C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024
16 juil. 2024 16h01 HE
|
C4 Therapeutics, Inc.
WATERTOWN, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation...
C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day
08 juil. 2024 07h00 HE
|
C4 Therapeutics, Inc.
WATERTOWN, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation...
C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors
10 juin 2024 07h00 HE
|
C4 Therapeutics, Inc.
Cooper Brings Decades of Global Pharmaceutical and Biotechnology Leadership Experience Bruce Downey Remains a Member of the Board of Directors and Chair of the Organization, Leadership and...
C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
08 mai 2024 07h00 HE
|
C4 Therapeutics, Inc.
Successfully Delivered First Development Candidate to Biogen; $8 Million Payment Earned Established a Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Focused on Two...
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
29 avr. 2024 16h01 HE
|
C4 Therapeutics, Inc.
WATERTOWN, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation...
C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum
09 avr. 2024 07h00 HE
|
C4 Therapeutics, Inc.
WATERTOWN, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation...
C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024
08 avr. 2024 08h00 HE
|
C4 Therapeutics, Inc.
WATERTOWN, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation...
C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024
05 mars 2024 16h30 HE
|
C4 Therapeutics, Inc.
WATERTOWN, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation...
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins
04 mars 2024 07h00 HE
|
C4 Therapeutics, Inc.
Collaboration Focused on Two Targeted Protein Degraders from C4T’s Internal Discovery Pipeline C4T to Receive a $16 Million Upfront Payment; Merck KGaA, Darmstadt, Germany, to Cover Discovery...
C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
22 févr. 2024 07h00 HE
|
C4 Therapeutics, Inc.
CFT1946 Preclinical Data Accepted for a Poster Presentation at the AACR Annual Meeting 2024 Phase 1 Dose Escalation Trials for CFT7455 and CFT1946 Continue to Progress; Data from Both Trials Expected...